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Abstract
Background: Bacteroides fragilis is the most frequent species at the human intestinal mucosal surface, it contributes
to the maturation of the immune system although is also considered as an opportunistic pathogen. Some Bifidobacterium
strains produce exopolysaccharides (EPS), complex carbohydrate polymers that promote changes in the metabolism of
B. fragilis when this microorganism grows in their presence. To demonstrate that B. fragilis can use EPS from bifidobacteria
as fermentable substrates, purified EPS fractions from two strains, Bifidobacterium longum E44 and Bifidobacterium animalis
subsp. lactis R1, were added as the sole carbon source in cultures of B. fragilis DSMZ 2151 in a minimal medium. Bacterial
counts were determined during incubation and the evolution of organic acids, short chain fatty acids (SCFA) and
evolution of EPS fractions was analysed by chromatography.
Results: Growth of B. fragilis at early stages of incubation was slower in EPS than with glucose, microbial levels remaining
higher in EPS at prolonged incubation times. A shift in metabolite production by B. fragilis occurred from early to
late stages of growth, leading to the increase in the production of propionate and acetate whereas decrease
lactate formation. The amount of the two peaks with different molar mass of the EPS E44 clearly decreased along
incubation whereas a consumption of the polymer R1 was not so evident.
Conclusions: This report demonstrates that B. fragilis can consume some EPS from bifidobacteria, with a
concomitant release of SCFA and organic acids, suggesting a role for these biopolymers in bacteria-bacteria
cross-talk within the intestine.
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Background
The colonic microbiota is a complex community whose
metabolic activity influences our health and nutritional
status through diverse pathways [1]. Microbiota of adult
healthy people is dominated by the phyla Firmicutes and
Bacteroidetes, even though the composition at the spe-
cies level is highly variable among individuals [2, 3].
Members of this microbiota are able to degrade complex
polysaccharides and, therefore, genes involved in the
degradation and consumption of these compounds are
widespread among the genomes of microbiota-resident
species [4, 5]. In this respect, the genus Bacteroides has
the ability to use a wide range of carbohydrates, this
ability varying as depending on the species considered
[6]. Bacteroides is an anaerobic, bile-resistant, non-spore
forming, and Gram negative rod [7] that accounts for up
to 20–50 % of the total microbiota in most individuals
[8]. Bacteroides fragilis is the most frequent species at
the mucosal surface [9] and can contribute to the devel-
opment and maturation of the host immune system [10].
This species has an extraordinarily good adaptability to
environmental changes due to its capacity to regulate
the cell surface [11]. Consequently B. fragilis is the clinical
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isolate most frequently found in systemic infections, this
microorganism being then considered as an opportunistic
pathogen [7].
Exopolysaccharides (EPS) are complex carbohydrates
located outside the cell; some Bifidobacterium strains, as
well as many other microorganisms, are able to produce
these polymers [12]. The synthesis of these compounds
in the intestine has not been demonstrated yet. However,
it has been proven in vitro that the presence of bile,
which is released to the small intestine during digestion,
stimulates the production of EPS by bifidobacteria [13].
EPS could be constituted either by a unique type of
monomer, named as homopolysaccharides (HoPS), or
by more than one monosaccharide type, then known as
heteropolysaccharides (HePS). All bifidobacterial EPS
characterized until present are HePS [14].
Differential growth of members from the genus Bacter-
oides in the presence of EPS isolated from Lactobacillus
and Bifidobacterium strains has been previously reported
[15, 16]. Particularly, two EPS fractions isolated from
Bifidobacterium longum E44 and Bifidobacterium animalis
subsp. lactis R1, have shown the capacity to act as ferment-
able substrates by the intestinal microbiota, thus promoting
the increase of Bacteroides populations in faecal cultures
[15, 17]. Specific changes have been demonstrated as
well in the metabolism of B. fragilis when grown in an
undefined and complex medium in the presence of EPS
E44 and R1 as compared with cultures in glucose [18].
Although these studies suggest that Bacteroides can use
bifidobacterial EPS as fermentable substrates, this had
not yet been effectively proven. In the present work, we
assessed this question by testing the ability of B. fragilis
DSMZ 2151 to growth in a minimal medium at the ex-
penses of EPS from bifidobacteria when they are the
sole carbon and energy source available.
Methods
Bacterial strains and culture media
Frozen stocks of B. fragilis DSMZ 2151 (DSMZ bacterial
pure collection, Braunschewig, Germany) were reacti-
vated in Gifu anaerobic medium (GAM) broth (Nissui
Pharmaceutical Co., Tokyo, Japan) supplemented with
0.25 % (w/v) L-cysteine (Sigma Chemical co., St. Louis,
MO, USA) (named GAMc) and incubated overnight at
37 °C in an anaerobic cabinet (Mac 100; Don Whitley
Scientific, West Yorkshire, UK) under a 10 % H2, 10 %
CO2, and 80 % N2 atmosphere. pH free batch cultures of
B. fragilis were performed in a modified minimal medium
(MM) previously used in B. fragilis metabolism studies
[19]. Briefly, the medium contained per litre: (NH4)2SO4,
1 g; KH2PO4, 0.9 g; NaCl, 0.9 g; CaCl2 · 2H20, 26.5 mg;
MgCl · 6H20, 20 mg; MnCl2 · 4H20, 10 mg; FeSO4 · 7H20,
4 mg; CoCl2 · 6H20, 1 mg; resazurin, 1 mg; vitamin B12,
10 μg; vitamin K1, 2 mg; and haemin, 4 mg. MM was sup-
plemented with 0.5 % (w/v) of glucose, EPS E44 or EPS R1
and the final pH of the medium ranged between 7.6 and
7.9. MM was inoculated with a 1 % (v/v) overnight culture
of B. fragilis in GAMc in a final volume of 10 mL. A cul-
ture of B. fragilis inoculated in MM without carbon source
added was used as a negative control. Potential changes
over time in the characteristics of the EPS fractions during
incubation not due to the microbial action were moni-
tored in uninoculated MM added with EPS. Bacterial
growth was monitored by counting in agar-GAMc plates
at 0, 24, 48, 72 and 144 h of incubation. Experiments
were run in triplicate using the same inoculum in all
conditions.
EPS isolation
The EPS fractions were obtained from the strains B. ani-
malis subsp. lactis IPLA R1 [20], a dairy origin strain, and
B. longum IPLA E44 [21], a faecal isolate from a healthy
adult faeces. Cellular biomass was harvested with ultrapure
water from agar-MRS (Biokar, Allone, France) plates with
0.25 % (w/v) L-cysteine (Sigma) and incubated for 3 days at
37 °C under anaerobic conditions [22]. In brief, EPS was
separated from the cellular biomass by gently stirring over-
night with one volume of 2 M NaOH at room temperature.
Then, cells were removed by centrifugation and EPS were
precipitated from the supernatant with two volumes of
absolute cold ethanol for 48 h at 4 C. After centrifugation
at 10,000 x g for 30 min at 4 C, the EPS fraction was resus-
pended in ultrapure water and dialyzed against water dur-
ing 3 days in 12- to 14-kDa molecular weight cut off
dialysis tubes (Sigma). The protein content of the poly-
mers was determined by the BCA protein assay kit (Pierce,
Rockford, IL, USA) following the manufacturer’s instruc-
tions. Finally, EPS fractions were freeze-dried. The EPS
E44 and R1 fractions contained 2.25 % and 1.99 % protein,
respectively.
To check the purity of the EPS and test for the eventual
presence of bacterial glycogen, EPS E44 and R1 fractions
and glycogen (Roche, Switzerland) were digested with α-
amylase (Sigma, USA) and/or pullulanase (Sigma, USA)
and degradation profiles were compared. Digested samples
were run in a TLC gel as described by Koropatkin and
Smith [23]. In brief, each reaction mixture contained
1 mg/mL of substrate (EPS R1, EPS E44 or commercial
glycogen) and 22 μg/mL of one or both enzymes in a
20 mM HEPES buffer. After 4 h of digestion at 37 °C, 6 μl
of each sample reaction were placed and dried in a TLC
Silica Gel 60 (Merk, Germany). Gels were transferred to a
solvent chamber with a 3:1:1 mixture of isopropanol: ethy-
lacetate: water, run for 3 h and revealed by irrigating a 5 %
sulfuric dilution in ethanol and were dried at 120 C° for
10 min. (Additional file 1: Figure S1).
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Metabolite analysis and EPS molar mass distribution and
quantification
Organic acids (lactic, succinic and formic) formed during
incubation were analysed by HPLC. Cell-free supernatants
from cultures were filtered (0.2 μm) and quantified using
an Alliance 2695 module injector, a PDA 966 photodiode
array detector, a 2414 differential refractometer detector
and the Empower software (Walters, Mildford, MA),
following the chromatographic conditions described
previously [22]. The weight average molar mass (Mw)
distribution of EPS fractions was determined in the
same equipment by size-exclusion chromatography (SEC)
using two different columns placed in series, TSK-Gel
G3000 PWxL and TSK-Gel G5000 PWxL (Supelco-Sigma)
and the multiangle laser light scattering (MALLS) detector
DawnHeleos II (Wyatt Europe GmbM, Dembach,
Germany) as described previously [22]. The EPS peaks
were detected and quantified with the refractive index
detector, using standards of dextran (Fluka-Sigma) of
different molar masses; the presence of proteins was
monitored through a PDA detector set at 220 nm [17].
Short chain fatty acids (SCFA; acetic and propionic)
were quantified in the supernatants by Gas Chromatog-
raphy (GC) using a system composed of a 6890 N gas
chromatograph (Agilent Technologies Inc., Palo Alto,
CA, USA) connected with a FID detector (Agilent) and
a mass spectrometry (MS) 5973 N detector (Agilent) as
described previously [15]. Concentrations were expressed
in millimolar (mM).
Statistical analysis
One way ANOVA statistical tests was run to compare
the evolution of the different parameters analysed along
time or among cultures with the different carbon and
energy sources by means of the IBM SPSS software, version
22.00 (IBM, Armonk, New York, USA). SNK post-hoc test
was used when required.
Results
The digestion pattern of EPS fractions E44 and R1 with
the enzymes α-amylase (endohydrolysis of 1,4- α-D-
glucosidic linkages) and pullulanase (endohydrolysis of
1,6-α-D-glucosidic linkages), were clearly different from
that of glycogen (Additional file 1: Figure S1). This indi-
cates that the release of intracellular glycogen during the
process of obtaining the EPS fractions is negligible.
Therefore, the results obtained through our work should
be related with EPS polymers.
The metabolite production and growth pattern of B.
fragilis DSMZ 2151 was dependent on the carbon source
present in the culture medium. The final pH attained
with glucose (6.52 ± 0.16) was significantly lower than with
EPS E44, EPS R1, and without carbon source (p < 0.05)
(7.62 ± 0.02, 7.66 ± 0.01 and 7.73 ± 0.05 respectively). The
pH values remained unchanged in MM without carbon
source added whereas bacterial counts increased 1.3 log
units from time 0 (7.02 ± 0.08 log ufc mL−1) to 24 h of
incubation in such conditions, probably due to the
metabolic inertia of the inoculum (Table 1). At 24 h of
incubation microbial counts reached were 1.22 log ufc
mL−1 higher in glucose and 0.6–0.8 greater in EPS than
in the control MM medium without any carbon source
added (p < 0.05) (Table 1). From that point on, the time
course of B. fragilis growth was different depending on
the carbon source, and microbial population levels
remained generally higher in EPS than in glucose at late
stages of growth (from 48 h of incubation) (Table 1).
Thus, microbial counts in glucose continuously de-
creased from 24 h to the end of incubation (p < 0.05).
In contrast, levels of B. fragilis with both EPS remained
largely unchanged from 24 to 72 h. From that time
population levels decreased with both polymers, this
decrease being much more pronounced with EPS R1
than with EPS E44.
The production of fermentation end-products from
the catabolism of carbohydrates by B. fragilis was not-
ably higher in glucose than in EPS and also in medium
with the different EPS than in the medium without
carbohydrates added all along the incubation period
considered in the study (p < 0.05) (Table 1). Glucose
was depleted in the culture medium after 24 h (data
not shown) and metabolite levels remained without
noticeable variations until 144 h of incubation. In contrast,
total metabolites produced in medium with both EPS
increased continuously until the end of fermentation,
reaching clearly higher levels at the end of the incuba-
tion period in the culture with EPS E44 than in EPS R1
(p < 0.05). We analysed more in depth the evolution
pattern of the different organic acids and SCFA formed
during incubation (Table 1). The acetic to propionic
acids ratio displayed higher values in glucose than in
both EPS (p < 0.05) whereas, conversely, the propionic
to succinic as well as the acetic to lactic acid ratios
showed a trend (p < 0.1) to display higher values in cul-
tures with EPS than with glucose. Regarding levels of
the different microbial metabolites in cultures with
EPS, the acetic, propionic and succinic acids increased
until 24 h, decreased from 24 to 48–72 h, and increased
again until the end of incubation. On the opposite, the
concentration of lactic acid reached the maximum value
at 48 h and then experienced a continuous decrease until
the end of incubation (p < 0.05). As a consequence, at 48 h
the acetic to lactic acid ratio reached its minimum value
whereas the acetic to propionic ratio attained its max-
imum in cultures with EPS E44.
Since the only carbon source available in our experimen-
tal conditions were either glucose or EPS, we examined
the evolution of the EPS fractions over time, looking
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Table 1 Growth and metabolic parameters of B. fragilis grown in glucose, EPS or without carbon source
Carbon source Time (h) Acetic acid Propionic acid Lactic acid Succinic acid Formic acid Total metabolites* Acetic/Propionic Propionic/Succinic Acetic/Lactic Bacterial counts+
Glucose 24 13.00 ± 0.41D 4.35 ± 0.63C 14.81 ± 0.27B 3.46 ± 0.19a B 7.33 ± 0.15D 42.95 ± 1.40a C 3.02 ± 0.35C 1.25 ± 0.12A 0.88 ± 0.01A 9.58 ± 0.07d C
48 13.28 ± 0.74C 4.69 ± 0.21C 17.11 ± 1.26B 3.75 ± 0.27a B 6.86 ± 0.38D 45.73 ± 1.22ab D 2.83 ± 0.08D 1.25 ± 0.13A 0.78 ± 0.07A 8.47 ± 0.16c B
72 13.80 ± 0.53C 5.04 ± 0.47D 16.15 ± 1.01B 4.37 ± 0.18b C 7.59 ± 0.12C 47.11 ± 0.41b C 2.75 ± 0.18D 1.15 ± 0.09A 0.86 ± 0.09 7.76 ± 0.06b A
144 13.66 ± 0.26D 4.96 ± 0.32D 15.27 ± 0.87B 4.56 ± 0.52b B 7.26 ± 0.45C 46.02 ± 1.96ab D 2.76 ± 0.15C 1.09 ± 0.06A 0.90 ± 0.05A 7.46 ± 0.17a B
EPS E44 24 1.24 ± 0.06b B 0.78 ± 0.08b A,B 0.45 ± 0.07b A 0.12 ± 0.02A 0.43 ± 0.04a B 3.01 ± 0.11a B 1.60 ± 0.10a B 6.78 ± 0.27D 2.83 ± 0.53a A 9.17 ± 0.12c B
48 0.93 ± 0.08a A,B 0.39 ± 0.08a A 0.95 ± 0.05c A - 1.27 ± 0.24b C 3.56 ± 0.22b C 2.44 ± 0.30b C ND 0.98 ± 0.12a A 8.91 ± 0.02b C
72 1.89 ± 0.10c B 0.95 ± 0.13b B 0.77 ± 0.08c A - 1.67 ± 0.46b B 5.31 ± 0.34c B 2.01 ± 0.19ab C ND 2.48 ± 0.38a 9.05 ± 0.05bc B
144 5.53 ± 0.08d C 2.75 ± 0.13c C 0.26 ± 0.15a A 0.13 ± 0.05A 1.40 ± 0.31b B 10.07 ± 0.39d C 2.01 ± 0.12ab B 25.22 ± 11.55B 26.24 ± 12.29b A 8.68 ± 0.14a C
EPS R1 24 1.70 ± 0.11a C 1.37 ± 0.12b B 0.16 ± 0.10b A 0.26 ± 0.05b A 0.73 ± 0.25a C 4.22 ± 0.09a B 1.25 ± 0.03a B 5.40 ± 0.54b C 14.03 ± 7.32a B 9.01 ± 0.09b B
48 1.40 ± 0.22a B 0.82 ± 0.12a B 0.49 ± 0.09c A 0.15 ± 0.01a A 1.92 ± 0.12c B 4.81 ± 0.37b B 1.70 ± 0.08b B 5.64 ± 0.55b B 2.86 ± 0.12a B 9.17 ± 0.09b D
72 2.08 ± 0.10b B 1.44 ± 0.16b C 0.12 ± 0.09b A 0.26 ± 0.00b B 1.35 ± 0.18b B 5.25 ± 0.09b B 1.45 ± 0.11a B 5.62 ± 0.62b B 25.26 ± 19.65a 9.15 ± 0.13b B
144 3.13 ± 0.18c B 1.70 ± 0.09c B 0.02 ± 0.01a A 0.53 ± 0.02c A 1.27 ± 0.26b B 6.65 ± 0.34c B 1.85 ± 0.20b B 3.21 ± 0.29a A >100b B 6.73 ± 0.21a A
WCS 24 0.21 ± 0.05a A 0.26 ± 0.03a A - 0.11 ± 0.07a A 0.09 ± 0.03a A 0.72 ± 0.12a A 0.79 ± 0.12A 2.33 ± 0.43 B ND 8.36 ± 0.15c A
48 0.27 ± 0.05a A 0.34 ± 0.03b A - 0.21 ± 0.01b A 0.17 ± 0.03b A 1.01 ± 0.05a A 0.79 ± 0.10A 1.66 ± 0.21A ND 8.10 ± 0.06c A
72 0.35 ± 0.06a A 0.36 ± 0.00b A - 0.20 ± 0.03b A 0.17 ± 0.04b A 1.08 ± 0.02a A 0.99 ± 0.16A 1.83 ± 0.29 A ND 7.84 ± 0.11b A
144 0.66 ± 0.22b A 0.51 ± 0.05c A - 0.23 ± 0.05b A 0.26 ± 0.03c A 1.68 ± 0.35b A 1.28 ± 0.30A 2.30 ± 0.36 A ND 6.61 ± 0.19a A
Metabolite concentrations are expressed in mM, bacterial counts are expressed in ufc mL−1 Columns for the same carbon source with different lower case letter superscripts indicate significant differences along time
(p > 0.05). Different capital letters superscripts indicate significant differences among carbon sources at the same sampling point (p < 0.05). * Sum of acetic, propionic, lactic, succinic, formic and pyruvic acids. + Counts













for detectable variations in the amount and/or physico-
chemical characteristics of the polymer peaks that
could demonstrate their consumption. Peaks of EPS E44,
purified from the cellular biomass of Bif. longum E44, were
according to that previously reported [22] and consisted
in two polymers, one of 5 × 106 Da (E44 P1) representing
18.8 % of the total mass, and a second one of 9 × 103 Da
(E44 P2), representing 81.2 % (Additional file 2: Figure
S2). We ruled out any change in the molar mass distri-
bution of the EPS E44 fraction along incubation in un-
inoculated MM (data not shown). Interestingly, the
incubation of EPS with B. fragilis in the MM resulted
in a significant decrease in the amount of the higher
molar mass peak (E44 P1) of E44 from 48 h to 144 h of
incubation (p < 0.05) (Fig. 1a and b) and of the smaller
molar mass peak (E44 P2) between 48 and 72 h of incuba-
tion, remaining stable from 72 to 144 h (p < 0.05) (Fig. 1a
and b). Molar mass distribution of EPS R1 was also in
accordance with that previously reported by us [24],
and consisted of three peaks; one of 1 × 106 Da (R1 P1),
another one of 2.35 × 104 Da (R2 P2) and a small one
of 4 × 103 Da (R3 P3). This last peak overlapped in our
analysis with an UV absorption peak and was then ex-
cluded from our study (Additional file 2: Figure S2).
The total amount of the higher molar mass R1 polymer
(R1 P1) did not show a decrease at the end of incubation,
independently on the presence of B. fragilis (Fig. 1d). The
amount of the medium size polymer (R1 P2) suffered an
apparent depletion along incubation, which reached statis-
tical significance at late incubation times (48, 72 and
144 h, p <0.05); however, the final amount of this polymer
in the MM without B. fragilis was not significantly differ-
ent (p > 0.05) from the values obtained in the culture with
bacteria added (Fig. 1c and d) (statistical data not shown).
Fig. 1 Time course of the bifidobacterial EPS degradation by B. fragilis. Refractive index chromatogram for degradation of EPS E44 peaks along
time (a). Evolution of the total amount of EPS E44 peaks along time (b). Refractive index chromatogram for degradation of EPS R1 peaks along
time (c). Evolution of the total amount of the two biggest peaks of EPS R1 fraction along time (d). Significant reduction of the amount of EPS in
the corresponding peak with respect to time 0 is indicated by asterisks (p < 0.05). Dashed red lines indicate the amount of polymer for each peak
after 144 h of incubation in the absence of B. fragilis
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Discussion
The use of bacterial EPS by Bacteroides thetaiotaomicron
has been described before with HoPS produced by some
lactic acid bacteria and Streptococcus spp. [6, 16, 25]. Al-
though the use of HePS from bifidobacteria had not been
definitely demonstrated yet, we have previously identified
changes in the metabolism of B. fragilis in the presence of
these polymers in an undefined medium [18]. Results from
the current study demonstrated an effective growth of this
specie in the presence of HePS. As compared to glucose,
Bacteroides population levels attained with our EPS at
early stages of growth were lower, but probably the slow
utilization of these polymers and hence their availability
as carbon source along incubation contributed to main-
tain the microbial levels at late states of growth, this
phenomenon being more pronounced with EPS E44
than with EPS R1. Besides, a differential metabolic ac-
tivity of B. fragilis in the presence of EPS as compared
to glucose was evidenced. B. fragilis remained metabolic-
ally active in cultures with EPS for a longer period of time,
with the highest activity corresponding to the cultures
with the polymer E44. Variations obtained in metabolic
profiles of Bacteroides cultures as depending on the car-
bon sources were similar to those indicated previously by
us using an undefined medium [18]. Additionally, higher
propionic to succinic acid ratios with complex carbon
sources relative to glucose, similar to that found in the
current study, have been previously reported [26].
In the present study we observed a clear shift in the
metabolite production by B. fragilis during the time
course of fermentation in the presence of EPS with respect
to glucose, which was more pronounced with the polymer
E44 than with R1. Coinciding with the depletion in the
amount of EPS polymers from 48 h of incubation, a grad-
ual increase in the concentrations of acetic, propionic and
succinic acids and a decrease in the levels of lactic acid oc-
curred until the end of incubation. It has been previously
suggested that, in Bacteroides, the production of propion-
ate through the succinate/propionate pathway could be a
cell response to optimize cell energy production while
keeping the intracellular redox balance [18, 19]. Although
B. fragilis has the capacity to metabolize moderate
amounts of lactic acid [27] as well as amino acids [28], our
work was performed in a minimal medium, so that no
amino acid sources were available and the scarce con-
sumption of lactic acid that may occur does not explain
the growth and metabolic activity of the bacterium in such
conditions.
The results from SEC-MALS chromatography indi-
cated that B. fragilis was able to use the EPS E44 pro-
duced by Bif. longum as a fermentable substrate. The
chemical structure of EPS E44 has not been elucidated
yet but it is known that EPS E44 contains glucose and
galactose in its composition [22]. It is then possible that
the saccharolytic enzymatic machinery of B. fragilis
could include enzymes able to participate in the degrad-
ation of this complex substrate. On the other hand,
changes in growth and metabolic patterns occurring at
late stages of growth in EPS E44 could be related with
the cessation of consumption of the smaller peak beyond
72 h of incubation, and hence with a scarcity of carbon
source available from this time. Our results are not con-
clusive about the possible degradation of the EPS R1
fraction by B. fragilis. Even though there were no signifi-
cant changes attributable to the activity of B. fragilis in
the EPS peaks of high and medium molar mass, we
could not rule out changes in the amount of the smallest
polymer, not considered in our study because the over-
lapping with a protein peak. Variations in this small
polymer may provide a possible explanation for the in-
creased metabolic activity evidenced in cultures of B.
fragilis until 72 h of incubation in the presence of the
EPS R1 fraction as compared to the control in MM
without carbon sources added. The EPS R1 fraction is
formed by glucose, galactose and rhamnose [24] and
only the chemical structure of the high molar mass peak
has been determined to date, which is composed by
50 % rhamnose [29]. Although we know that the pres-
ence of both EPS stimulates the production of α-
glucosidase by B. fragilis, the high molar mass polymer
of the EPS R1 fraction lacks the α-linkages targeted by
this enzymatic activity [29]. This together with the in-
ability of B. fragilis to ferment rhamnose [28], could
pose difficulties for the use as fermentable substrate of
the EPS R1 by this microorganism.
The ability of B. fragilis to use bifidobacterial EPS may
provide this microorganism with a long-term available
complex carbon source, thus enhancing its survival and
conferring it a selective advantage in environments where
nutrients are scarce, such as the case of the human large
intestine. Bacteroides plays an important role in the
utilization of indigestible dietary compounds and complex
polymers secreted by other microorganisms [6]. Some EPS
and capsular polysaccharides are involved in adhesion to
eukaryotic cells, biofilm formation and protection of sev-
eral species against the gastrointestinal stressing factors
[14]. In this way the ability of Bacteroides to degrade these
polymers may confer this microorganism a role in the
regulation of microbial relationships in the gut ecosystem.
Fermentation of EPS in faecal cultures lead to an increase
in propionic acid production [17], most likely due to the
metabolic activity of members from the genus Bacteroides.
Conclusions
The present work is the first report demonstrating that
B. fragilis is able to use some EPS produced by a bifido-
bacteria as substrate for growth, which resulted in a par-
tial polymer consumption and the concomitant release
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of metabolic end products from its fermentation. By ex-
trapolating these findings to the human gut, it may be
hypothesized that the feeding relationship between mi-
crobial EPS and Bacteroides could have an impact in the
SCFA production balance in the gut, which is ultimately
related with the human health.
Additional files
Additional file 1: Figure S1. Thin layer chromatography of the
digestion of glycogen and EPS E44 and R1 fractions with enzymes
α-amylase, pullulanase, and with a mixture of α-amylase and pullulanase.
(PPTX 522 kb)
Additional file 2: Figure S2. Size exclusion chromatography (SEC-MALS)
analysis of the EPS E44 (A) and EPS R1 (B) fractions purified from the cell
biomass of Bifidobacterium longum E44 and Bifidobacterium animalis subsp.
lactis R1, respectively. Refractive index detector (blue line) for detection and
quantification of EPS peaks, PDA detector (green line) set at 280 nm to
identify the presence of proteins, and the multiangle laser light scattering
(MALS) for molar mass distribution of the EPS fractions (red line).
(PPTX 758 kb)
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